TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

In a challenging market environment, TNFA stock has reached a new 52-week low, with shares plummeting to $0.48. According to InvestingPro data, the stock's RSI indicates oversold conditions ...

TNF Pharmaceuticals (TNFA) announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer ...

US Trade Policy: Wide-ranging Tariff Increases Heighten Global Credit RiskThu, 10 Apr 2025 12:20:56 GMT US-China Trade War: Yuan Sinks as US Tariff Pressure Mounts, Eyes on BeijingThu, 10 Apr 2025 ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BALTIMORE, March 17, 2025--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...